E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Sickle Cell Disease |
Anemia falciforme |
|
E.1.1.1 | Medical condition in easily understood language |
Sickle Cell Disease |
Anemia falciforme |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040644 |
E.1.2 | Term | Sickle cell disease |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effect of ticagrelor vs placebo for the reduction of VOCs, which is the composite of painful crisis and/or ACS, in paediatric patients with SCD |
Comparare l’effetto di ticagrelor rispetto al placebo per la riduzione di CVO, che è un misto di crisi di dolore e/o ACS, in pazienti pediatrici affetti da AF. |
|
E.2.2 | Secondary objectives of the trial |
- compare the effect of ticagrelor vs placebo for reduction of; painful crises, ACS, duration of painful crises, days hospitalised for VOC, days hospitalised for acute SCD complications - compare the effect of ticagrelor vs placebo on the number of VOCs requiring hospitalisation or emergency department visits - compare the effect of ticagrelor vs placebo on the number of acute SCD complications - compare the effect of ticagrelor vs placebo on the number of sickle cell-related red blood cell (RBC) transfusions - describe the health-related quality of life (HRQL) and fatigue - describe intensity of pain during VOC |
-Comparare l’effetto di ticagrelor rispetto al placebo per la riduzione di crisi di dolore, ACS, durata di crisi dolorose, riduzione dei giorni di ricovero per CVO, giorni di ricovero per complicanzea acute di AF -Comparare l’effetto di ticagrelor rispetto al placebo sul numero di CVO che richiedono ricovero o visite al pronto soccorso -Comparare l’effetto di ticagrelor rispetto al placebo sul numero di complicanzea acute di AF - Comparare l’effetto di ticagrelor rispetto al placebo sul numero di trasfusioni di eritrociti relative all’anemia falciforme - Descrivere la qualità della vita correlata alla salute (HRQL) e l’affaticamento - Descrivere l’intensità del dolore durante la CVO |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female paediatric patients aged > or =2 to <18 years and body weight of > or =12 kg (at Visit 1), diagnosed with HbSS or HbS/ß0 as confirmed by high-performance liquid chromatography or haemoglobin electrophoresis. 2. Have experienced at least 2 VOCs (painful crisis and/or ACS) as judged by the Investigator in the past 12 months prior to Visit 1. These VOCs need to be documented in the patient’s medical records or in other documents that can be reconciled. 3. Prior to dosing on day of randomisation (Visit 2), a negative urine (dipstick) pregnancy test performed at Screening (Visit 1) and at Visit 2 must be available for female patients of childbearing potential. 4. Females of childbearing potential (after menarche) must not become pregnant during study. Sexually active females must use a highly effective method of contraception which results in a low failure rate (ie, less than 1% per year). If use of effective contraception cannot be secured in sexually active females, the patient cannot be included in this study. |
1. Male or female paediatric patients aged > o =2 to <18 years and body weight of > o =12 kg (at Visit 1), diagnosed with HbSS or HbS/ß0 as confirmed by high-performance liquid chromatography or haemoglobin electrophoresis. 2. Have experienced at least 2 VOCs (painful crisis and/or ACS) as judged by the Investigator in the past 12 months prior to Visit 1. These VOCs need to be documented in the patient’s medical records or in other documents that can be reconciled. 3. Prior to dosing on day of randomisation (Visit 2), a negative urine (dipstick) pregnancy test performed at Screening (Visit 1) and at Visit 2 must be available for female patients of childbearing potential. 4. Females of childbearing potential (after menarche) must not become pregnant during study. Sexually active females must use a highly effective method of contraception which results in a low failure rate (ie, less than 1% per year). If use of effective contraception cannot be secured in sexually active females, the patient cannot be included in this study. |
|
E.4 | Principal exclusion criteria |
1. History of transient ischaemic attack (TIA) or cerebrovascular accident (ischaemic or haemorrhagic), severe head trauma, intracranial haemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or proliferative retinopathy. 2. Findings on TCD: Current or previous values for time averaged mean of the maximum velocity (TAMMV) that are Conditional or Abnormal. Patients with Conditional TAMMV values or higher (> or =153 cm/sec using TCD imaging technique which is corresponding to > or =170 cm/sec by the non-imaging technique). Both the middle cerebral artery and the internal carotid artery should be considered. Any other criteria that would locally be considered as TCD indications for chronic transfusion would also exclude the patient. 3. Active pathological bleeding or increased risk of bleeding complications according to Investigator 4. Haemoglobin <6 g/dL from test performed at Screening (Visit 1) 5. Platelets <100 x (10)9/L from test performed at Screening (Visit 1) 6. Undergoing treatment with chronic red blood cell transfusion therapy 7. Chronic use of NSAIDs defined as continuous intake >3 days per week that cannot be discontinued 8. Receiving chronic treatment with anticoagulants or antiplatelet drugs that cannot be discontinued 9. Moderate or severe hepatic impairment defined as laboratory values of alanine aminotransferase (ALT) >2 × upper limits of normal (ULN), total bilirubin (TB) >2 × ULN (unless judged by the Investigator to be caused by haemolysis), albumin <35 g/L (3.5 g/dL) and International normalised ratio (INR) >1.4, or symptoms of liver disease (eg, ascites) from test performed at Screening (Visit 1). 10. Renal failure requiring dialysis 11. Patient considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second or third degree atrioventricular block) unless already treated with a permanent pacemaker. 12. Concomitant oral or intravenous therapy with strong cytochrome P450 3A (CYP3A) inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers, which cannot be stopped at least 5 half-lives before randomisation. 13. Active untreated malaria. Patients with suspected malaria at Screening (Visit 1) will be tested. 14. Known hypersensitivity or contraindication to ticagrelor 15. Patients who are currently pregnant or breastfeeding, or planning to become pregnant during the study or have given birth less than 3 months prior to Screening (Visit 1) 16. Any condition which, in the opinion of the Investigator, would make it unsafe or unsuitable for the patient to participate in this study 17. Concern for the inability of the patient or caregiver (defined as legally authorised representative) to comply with study procedures and/or follow-up 18. Previous randomisation in the present study 19. Participation in another clinical study with an IP or device during the last 30 days preceding enrolment. 20. Involvement of member of patient’s family, or patient self, in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). |
1. History of transient ischaemic attack (TIA) or cerebrovascular accident (ischaemic or haemorrhagic), severe head trauma, intracranial haemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or proliferative retinopathy. 2. Findings on TCD: Current or previous values for time averaged mean of the maximum velocity (TAMMV) that are Conditional or Abnormal. Patients with Conditional TAMMV values or higher (> or =153 cm/sec using TCD imaging technique which is corresponding to >or =170 cm/sec by the non-imaging technique). Both the middle cerebral artery and the internal carotid artery should be considered. Any other criteria that would locally be considered as TCD indications for chronic transfusion would also exclude the patient. 3. Active pathological bleeding or increased risk of bleeding complications according to Investigator 4. Haemoglobin <6 g/dL from test performed at Screening (Visit 1) 5. Platelets <100 x (10)9/L from test performed at Screening (Visit 1) 6. Undergoing treatment with chronic red blood cell transfusion therapy 7. Chronic use of NSAIDs defined as continuous intake >3 days per week that cannot be discontinued 8. Receiving chronic treatment with anticoagulants or antiplatelet drugs that cannot be discontinued 9. Moderate or severe hepatic impairment defined as laboratory values of alanine aminotransferase (ALT) >2 × upper limits of normal (ULN), total bilirubin (TB) >2 × ULN (unless judged by the Investigator to be caused by haemolysis), albumin <35 g/L (3.5 g/dL) and International normalised ratio (INR) >1.4, or symptoms of liver disease (eg, ascites) from test performed at Screening (Visit 1). 10. Renal failure requiring dialysis 11. Patient considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second or third degree atrioventricular block) unless already treated with a permanent pacemaker. 12. Concomitant oral or intravenous therapy with strong cytochrome P450 3A (CYP3A) inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers, which cannot be stopped at least 5 half-lives before randomisation. 13. Active untreated malaria. Patients with suspected malaria at Screening (Visit 1) will be tested. 14. Known hypersensitivity or contraindication to ticagrelor 15. Patients who are currently pregnant or breastfeeding, or planning to become pregnant during the study or have given birth less than 3 months prior to Screening (Visit 1) 16. Any condition which, in the opinion of the Investigator, would make it unsafe or unsuitable for the patient to participate in this study 17. Concern for the inability of the patient or caregiver (defined as legally authorised representative) to comply with study procedures and/or follow-up 18. Previous randomisation in the present study 19. Participation in another clinical study with an IP or device during the last 30 days preceding enrolment. 20. Involvement of member of patient’s family, or patient self, in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of VOCs |
Number of VOCs |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Up to End of Study Visit {12 to 24 months} |
Up to End of Study Visit {12 to 24 months} |
|
E.5.2 | Secondary end point(s) |
- Number of painful crises - Number of ACSs - Duration of painful crises - Number of VOCs requiring hospitalisation or emergency department visits - Number of days hospitalised for VOC - Number of acute SCD complications - Number of days hospitalised for acute SCD complications - Number of sickle cell-related RBC transfusions - HRQL total score and by dimension using Paediatric Quality of Life Inventory (PedsQL) SCD Module and Fatigue total score and by dimension using the PedsQL Multidimensional Fatigue Scale - Intensity of worst pain daily during VOC |
- Number of painful crises - Number of ACSs - Duration of painful crises - Number of VOCs requiring hospitalisation or emergency department visits - Number of days hospitalised for VOC - Number of acute SCD complications - Number of days hospitalised for acute SCD complications - Number of sickle cell-related RBC transfusions - HRQL total score and by dimension using Paediatric Quality of Life Inventory (PedsQL) SCD Module and Fatigue total score and by dimension using the PedsQL Multidimensional Fatigue Scale - Intensity of worst pain daily during VOC |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Secondary end points will be measured up to Safety Follow up Visit (End of Study + 14 days) - HRQL (PedsQL) assessment will be performed at visits on day 0, 6mo, 12mo, 18mo, EOS (12-24 months) |
- Secondary end points will be measured up to Safety Follow up Visit (End of Study + 14 days) - HRQL (PedsQL) assessment will be performed at visits on day 0, 6mo, 12mo, 18mo, EOS (12-24 months) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Canada |
Egypt |
Ghana |
India |
Kenya |
Lebanon |
Saudi Arabia |
South Africa |
Tanzania, United Republic of |
Turkey |
Uganda |
United States |
Belgium |
Greece |
Italy |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |